Jane Street Group, LLC Annovis Bio, Inc. Transaction History

Jane Street Group, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$4.37 - $9.87 $209,327 - $472,782	47,901 Added 237.06%	68,107 $342,000
Q3 2024 Nov 14, 2024	BUY	$5.27 - $15.46 $53,137 - $155,883	10,083 Added 99.6%	20,206 $162,000
Q2 2024 Aug 14, 2024	BUY	$4.82 - $18.01 $48,792 - $182,315	10,123 New	10,123 $58,000
Q4 2023 Feb 14, 2024	BUY	$5.55 - $19.62 $66,427 - $234,831	11,969 New	11,969 $223,000
Q1 2023 May 15, 2023	BUY	$12.33 - $22.1 $183,347 - $328,627	14,870 New	14,870 $229,000

2.18M

88.1K

188K

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $22.6M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.